Skip to main content
. Author manuscript; available in PMC: 2020 Feb 4.
Published in final edited form as: Antiviral Res. 2018 Dec 3;162:61–70. doi: 10.1016/j.antiviral.2018.11.012

Figure 1: Virus titers in tissues after infection with mouse-adapted EV-D68.

Figure 1:

Comparison of virus titers in blood, lungs, liver, kidney and spleen after infection with mouse passaged (MP) viruses. MP30 showed similar significance against MP20 and plaque purified MP30 (MP30pp) virus in kidney tissue. All mice were challenged with 10^6.5 CCID50 of the respective viruses in a 90 μl volume. *P<0.05, **P<0.01, ***P<0.001.